Research Analysts Set Expectations for ATNM Q1 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Actinium Pharmaceuticals in a research report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.33) EPS.

Separately, Stephens reiterated an “overweight” rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.50.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $0.99 on Wednesday. The company has a market capitalization of $30.88 million, a P/E ratio of -0.71 and a beta of -0.31. Actinium Pharmaceuticals has a 1 year low of $0.95 and a 1 year high of $1.95. The company’s fifty day moving average is $1.14 and its two-hundred day moving average is $1.35.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Actinium Pharmaceuticals by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after buying an additional 12,703 shares during the last quarter. Mayport LLC acquired a new position in Actinium Pharmaceuticals in the 3rd quarter valued at $35,000. AM Investment Strategies LLC purchased a new position in Actinium Pharmaceuticals during the 4th quarter worth $40,000. Bank of America Corp DE raised its position in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after buying an additional 34,176 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Actinium Pharmaceuticals by 278.6% in the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after acquiring an additional 46,545 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.